SAN JOSE, Calif., May 16 /PRNewswire/ -- InjecTx, Inc., a privately-owned technology development company, today announced that it has entered into a non-exclusive patent license agreement with American Medical Systems Holdings, Inc. , granting AMS rights to develop devices for injections directly into the bladder and the prostate. Terms of the patent licensing agreement were not disclosed.
Simultaneously, InjecTx, Inc. announced AMS is transferring the distribution rights for the ProstaJect product back to InjecTx. ProstaJect, a transurethral injection device delivering ethanol to the prostate, was being marketed by AMS outside the U.S. as a minimally invasive BPH treatment. InjecTx plans to immediately begin marketing the product under the trademark InjecTx. InjecTx anticipates a seamless transition for ProstaJect customers, and plans to continue to provide high quality service to hospitals, physicians and patients. InjecTx reports that the device can also be used to inject various therapeutic agents and biomaterials to treat urological disorders.
“We are excited to sign this patent license agreement with AMS, a worldwide leader in surgical urology. Injection treatments in the prostate and bladder represent an emerging growth opportunity in urology. Through this agreement, InjecTx is poised to participate in this high growth future market. The transfer of the ProstaJect product to InjecTx represents a new beginning and opportunity for our company,” commented Ashvin Desai, President and Chief Executive Officer of InjecTx, Inc. “The interstitial injection treatment under imaging guidance is a cost effective, next generation technology platform for minimally invasive treatment in a physician’s office. The targeted injection for the treatment of prostate, bladder, liver, kidney, uterus, fibroids and other body organs represents a safe and affordable alternative for both patients and physicians around the world. The clinical applications and commercial potential of targeted injections with real time imaging modalities are significant.”
About InjecTx, Inc.
InjecTx, Inc. is a developer of state of the art technology based new products for treatment of urological, urogynecological and gynecological products. The Company develops, manufactures and markets innovative, cost effective treatment options for Men’s health and Women’s health. InjecTx is a FDA approved establishment with ISO 13485:2003 certification and has received CE Mark for its products. The Company’s products and treatment options can be reviewed by visiting its website www.InjecTx.com.
Contact: Mirtha Vargas Investor Relations 408-945-4044
InjecTx, Inc.
CONTACT: investors, Mirtha Vargas of InjecTx, Inc., +1-408-945-4044
Web site: http://www.InjecTx.com//
